Radioactive probes could light up pancreatic tumors for smarter treatment

NCT ID NCT06602037

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests three new radioactive imaging probes that attach to proteins found on pancreatic cancer cells. By using PET/CT scans, doctors hope to see where the cancer has spread and predict which patients might respond to targeted drugs. The trial will enroll 90 adults with confirmed or suspected pancreatic cancer. Each participant will receive one or more of the probes and undergo multiple scans to measure how well the probes highlight tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
radioactive imaging probes ([89Zr]Zr-DFO-SHR1920, [18F]F-RESCA-3A12, [68Ga]Ga-NOTA-3A12)
What this could lead to
If successful, these imaging scans could help doctors see pancreatic tumors more clearly and identify patients who might benefit from targeted treatments.
What could go wrong
This is an early imaging study, not a treatment trial. The probes may not reliably distinguish tumors from normal tissue, and results may not change patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS, PANCREATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Renji Hospital, School of Medicine, Shanghai Jiao Tong University

    RECRUITING

    Shanghai, 200127, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.